Posted by John Deo
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) faces significant competition in developing treatments for gastro
Source: Two Blokes Trading
Posted by John Deo
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a biopharmaceutical company focused on developing treatments fo
Source: Two Blokes Trading
Posted by John Deo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has a Return on Invested Capital (ROIC) of -45.95% and a Weighte
Source: Two Blokes Trading
Posted by John Deo
Earnings per share (EPS) of $0.343, missing the estimated $0.39, marking a 12.82% negative surprise. Revenue
Source: Two Blokes Trading
Posted by John Deo
Significant increase in assets under management (AUM), reaching $36.5 billion, a 9.6% rise from the previous
Source: Two Blokes Trading
Posted by John Deo
TRATF reported an earnings per share (EPS) of $1.27, slightly below the estimated EPS of $1.33. The company's
Source: Two Blokes Trading
Posted by John Deo
Thomas Shrader from BTIG set a price target of $48 for NASDAQ:ARCT, indicating a significant potential upside
Source: Two Blokes Trading
Posted by John Deo
GoodRx's ROIC of 3.25% is significantly lower than its WACC of 11.62%, indicating inefficient capital utiliza
Source: Two Blokes Trading
Posted by John Deo
CSG Systems International, Inc. showcases efficient capital utilization with a ROIC of 12.11% and a WACC of 9
Source: Two Blokes Trading
Posted by John Deo
Perpetua Resources Corp. (NASDAQ:PPTA) is currently under investigation by Levi & Korsinsky for potential
Source: Two Blokes Trading
Posted by John Deo
Magnite's ROIC of 3.19% outperforms its closest peer, PubMatic, showcasing its effectiveness in generating re
Source: Two Blokes Trading
Posted by John Deo
Wall Street anticipates an earnings per share (EPS) of $3.49 and revenue of approximately $3.77 billion for t
Source: Two Blokes Trading